| Amir, Offer |
Copaxone, NCT06003972: Asses the Anti-inflammatory Effects of Short Term Therapy on Patients the Acute Decompensated Heart Failure |
|
|
| Completed | 2 | 14 | RoW | Copaxone, Glatiramer Acetate, guideline directed medical therapy (GDMT) | Hadassah Medical Organization, Weizmann Institute of Science | Acute Decompensated Heart Failure, Cytokine Storm, Inflammatory Response, Heart Failure | 03/23 | 03/23 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 11/25 | 01/26 | | |
| Yang, Wei |
NCT02654561: Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation |
|
|
| Recruiting | 3 | 600 | RoW | Heparin Sodium, Unfractionated heparin, Saline, Normal saline | China Medical University, China, West China Hospital, Zhongda Hospital, The First Affiliated Hospital of Dalian Medical University, Shengjing Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, The Second Affiliated Hospital of Kunming Medical University, The First Hospital of Qinhuangdao, The Second Affiliated Hospital of Dalian Medical University, First Affiliated Hospital of Harbin Medical University, Peking University People's Hospital, The People's Hospital of Liaoning Province, Fourth People's Hospital of Shenyang, Beijing Tsinghua Changgeng Hospital, First Affiliated Hospital of Kunming Medical University, The Affiliated Hospital of Qingdao University, Beijing Friendship Hospital, General Hospital of Ningxia Medical University, The First Affiliated Hospital of Nanchang University | Sepsis, Disseminated Intravascular Coagulation | 12/24 | 06/25 | | |
NCT05236621: A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma |
|
|
| Active, not recruiting | 3 | 85 | RoW | Pomalidomide, Dexamethasone | Qilu Pharmaceutical Co., Ltd. | Multiple Myeloma, Recurrent or Refractory | 06/22 | 12/23 | | |
APPROACH, NCT04841811: MRD Guiding Treatment After Almonertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model. |
|
|
| Recruiting | 3 | 192 | RoW | Almonertinib, ctDNA dynamic monitoring guided the Almonertinib treatment | Guangdong Association of Clinical Trials, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Lung Cancer | 12/24 | 12/26 | | |
NCT06312475: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors |
|
|
| Recruiting | 3 | 51 | RoW | KN057 | Suzhou Alphamab Co., Ltd. | Hemophilia A With Inhibitor, Hemophilia B With Inhibitor | 10/25 | 12/25 | | |
NCT06569108: Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors |
|
|
| Recruiting | 3 | 111 | RoW | KN057 | Suzhou Alphamab Co., Ltd. | Hemophilia A Without Inhibitor, Hemophilia B Without Inhibitor | 10/26 | 12/26 | | |
ALTN-AK105-III-02, NCT04344158: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Not yet recruiting | 3 | 648 | RoW | AK105 Injection, Anlotinib Hydrochloride Capsules, Sorafenib Tosylate Tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Hepatocellular Carcinoma (HCC) | 06/24 | 12/24 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
CMML1-2, NCT06647862: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia |
|
|
| Recruiting | 3 | 170 | RoW | IMM01, Timdarpacept, Azacitidine, Placebo | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Chronic Myelomonocytic Leukemia | 10/26 | 10/29 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 01/25 | 05/26 | | |
NCT04578613: ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL |
|
|
| Recruiting | 3 | 218 | RoW | ICP-022, Chlorambucil, Rituximab | Beijing InnoCare Pharma Tech Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/24 | 06/25 | | |
NCT05051891: A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 356 | RoW | Orelabrutinib and R-CHOP, R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Treatment-naїve Mantle Cell Lymphoma | 12/24 | 12/27 | | |
BRUIN-MCL-321, NCT04662255: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) |
|
|
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
NCT05618470: Wumeiwan Jiawei Fang Use in Patients With Blepharospasm |
|
|
| Recruiting | 2/3 | 80 | RoW | Wumeiwan Jiawei Fang, nothing, botulinum toxin A | China Academy of Chinese Medical Sciences | Dry Eye Syndromes, Meige Syndrome, Blepharospasm, Hyperactivity | 08/24 | 09/24 | | |
| Completed | 2 | 3 | RoW | ICP-022 | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma | 11/21 | 12/21 | | |
NCT05716087: A Study of Rocbrutinib in Participants with Relapse or Refractory Mantle Cell Lymphoma |
|
|
| Recruiting | 2 | 62 | RoW | Rocbrutinib, NWP-775, LP-168 | Guangzhou Lupeng Pharmaceutical Company LTD. | Mantle Cell Lymphoma (MCL) | 12/24 | 12/25 | | |
| Recruiting | 2 | 25 | RoW | STSP-0601 for Injection | Staidson (Beijing) Biopharmaceuticals Co., Ltd | Hemophilia | 02/25 | 02/25 | | |
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
NCT04390737: Evaluate the Safety and Clinical Activity of HH2853 |
|
|
| Recruiting | 1/2 | 254 | US, RoW | HH2853 Tablets | Haihe Biopharma Co., Ltd. | FL Lymphoma, Epithelioid Sarcoma, Peripheral T Cell Lymphoma, Advanced Solid Tumor | 12/25 | 12/25 | | |
NCT06580301: Study of YK012 in B-cell Acute Lymphoblastic Leukemia |
|
|
| Recruiting | 1/2 | 46 | RoW | YK012, YK012 for Injection | Excyte Biopharma Ltd | B-cell Acute Lymphoblastic Leukemia | 12/26 | 06/27 | | |
TQB3909-Ib/II-02, NCT05959694: A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . |
|
|
| Recruiting | 1/2 | 107 | RoW | TQB3909 tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 12/25 | 06/26 | | |
NCT05104775: A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy |
|
|
| Recruiting | 1 | 58 | RoW | GNC-035 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Hematologic Malignancies | 12/24 | 12/24 | | |
| Recruiting | 1 | 108 | RoW | GLB-001, GLB-C183-A-2 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myeloid Malignancy | 12/26 | 12/27 | | |
NCT06387082: A Clinical Study of HMPL-506 in Patients With Hematological Malignancies |
|
|
| Recruiting | 1 | 98 | RoW | HMPL-506, Two strengths of HMPL-506 tablets (25 mg and 100 mg) will be used for this clinical study | Hutchmed | Hematological Malignancies | 10/27 | 12/27 | | |
| Recruiting | 1 | 105 | RoW | ICP-248 | Beijing InnoCare Pharma Tech Co., Ltd. | Hematological Malignancies | 08/24 | 10/26 | | |
NCT05363800: Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma |
|
|
| Recruiting | 1 | 198 | RoW | HRS-3738 | Jiangsu HengRui Medicine Co., Ltd. | Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma | 10/24 | 12/24 | | |
| Recruiting | N/A | 2000 | RoW | | National Cancer Centre, Singapore, Duke-NUS Graduate Medical School, Singapore Phenome Centre, Nanyang Technological University, MiRXES Pte Ltd, Perspectum Asia Pte Ltd, Asian Microbiome Library Pte Ltd | Liver Diseases | 12/26 | 12/26 | | |
NCT06609434: The Role and Safety of Radiofrequency Ablation in Recurrent Liver Metastasis of Colorectal Cancer |
|
|
| Not yet recruiting | N/A | 111 | NA | Radiofrequency ablation | Peking University Cancer Hospital & Institute | Colo-rectal Cancer, Liver Metastasis | 12/26 | 12/26 | | |
NCT04724148: Impact of Fentanyl Analgesia on the Accuracy of HVPG Measurements in Patients With Portal Hypertension |
|
|
| Recruiting | N/A | 4 | RoW | Fentanyl | Hepatopancreatobiliary Surgery Institute of Gansu Province, LanZhou University, Lishui hospital of Zhejiang University, The First Affiliated Hospital with Nanjing Medical University, Zhejiang University | Liver Cirrhosis, Portal Hypertension, Pain | 11/24 | 11/24 | | |
| Enrolling by invitation | N/A | 2000 | RoW | BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System | Biotronik (Beijing) Medical Device Ltd., Biotronik AG | In-Stent Stenosis (Restenosis) of Coronary Artery Stent, Native Coronary Artery Stenosis | 12/24 | 12/29 | | |
NCT05013190: A Study of NINLARO® in Chinese Adults With Multiple Myeloma |
|
|
| Recruiting | N/A | 160 | RoW | No intervention | Takeda | Multiple Myeloma | 06/27 | 06/27 | | |
NCT04995159: Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVasâ„¢ BRS System |
|
|
| Not yet recruiting | N/A | 2150 | RoW | Single anti-platelet therapy, SAPT strategy, Dual anti-platelet therapy, DAPT strategy | Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Heart Disease | 01/26 | 01/28 | | |
| Merkely, Béla |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight and Obesity | 02/29 | 02/29 | | |
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events |
|
|
| Completed | 2 | 233 | Europe, Japan, US, RoW | LY3473329, Placebo | Eli Lilly and Company | Lipoprotein Disorder | 03/24 | 03/24 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 11/25 | 01/26 | | |
| Recruiting | N/A | 15 | Europe, Canada, RoW | VenTouch System | Mardil Medical | Functional Mitral Regurgitation | 05/21 | 12/23 | | |
NCT02893657: The Role and Dynamics of Liver Dysfunction in Patients Undergoing Cardiac Surgery |
|
|
| Recruiting | N/A | 150 | Europe | | Semmelweis University Heart and Vascular Center, Semmelweis University | Cardiac Surgery, Hepatic Impairment, Heart Failure | 05/22 | 05/23 | | |
| Completed | N/A | 360 | Europe, RoW | CRT-D | Semmelweis University Heart and Vascular Center, University of Rochester, Sheba Medical Center, Pharmahungary Group | Cardiomyopathy | 08/22 | 08/22 | | |
| Recruiting | N/A | 800 | Europe | Remote monitoring | Semmelweis University Heart and Vascular Center | Heart Failure | 06/25 | 08/25 | | |
NCT05462405: Evaluation of Sympathetic Activity Effects by the BackBeat Medical Cardiac Neuromodulation Therapy (CNT). |
|
|
| Recruiting | N/A | 15 | Europe | Experimental group | BackBeat Medical Inc | Hypertension | 09/23 | 12/23 | | |
NCT05719454: Novel Setup Algorithm for Cardiac Neuromodulation Therapy |
|
|
| Recruiting | N/A | 30 | Europe, RoW | CNT testing | BackBeat Medical Inc | Hypertension, Bradycardia | 07/24 | 10/24 | | |
INTENSE, NCT06603363: Changes in Plaque Characteristics After Short-term Statin Therapy As Assessed with Coronary CT |
|
|
| Not yet recruiting | N/A | 140 | Europe | Rosuvastatin 40mg, Intensified Statin Therapy, Placebo, Coronary Computed Tomography Angiography (Coronary CTA), Coronary CTA, Blood test, Laboratory test | Prof. Maurovich-Horvat Pál, National Research, Development and Innovation Office, Hungary | Coronary Artery Disease, Atherosclerotic Plaque, Coronary Computed Tomography Angiography, Statin Therapy, Multidetector Computed Tomography, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Vascular Diseases | 10/26 | 12/28 | | |
| Recruiting | N/A | 3000 | Europe, Japan, RoW | Cardiac Resynchronization Therapy (CRT) | Biotronik SE & Co. KG | Heart Failure | 12/24 | 06/25 | | |
NCT06048731: Enlighten Study: The EV-ICD Post Approval Registry |
|
|
| Recruiting | N/A | 1000 | Europe, Canada, US, RoW | Defibrillation using EV-ICD | Medtronic | Ventricular Arrhythmia, Tachycardia | 05/30 | 10/37 | | |
| Schenker, Michael |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 07/25 | | |
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
| Terminated | 3 | 166 | Europe, Canada, Japan, US, RoW | Xevinapant (Debio 1143), IMRT, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Head and Neck Cancer | 08/24 | 08/24 | | |
COSTAR Lung, NCT04655976 / 2020-003433-37: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy |
|
|
| Active, not recruiting | 3 | 758 | Europe, Canada, Japan, US, RoW | Cobolimab, Dostarlimab, Docetaxel | GlaxoSmithKline | Lung Cancer, Non-Small Cell | 04/25 | 10/25 | | |
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 43 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 06/24 | 12/25 | | |
|
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation |
|
|
| Recruiting | 3 | 400 | Europe, Canada, US, RoW | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Sermonix Pharmaceuticals Inc. | Metastatic Breast Cancer | 06/25 | 06/26 | | |
| Active, not recruiting | 3 | 615 | Europe, Canada, US, RoW | Oregovomab, MAb-B43.13, Paclitaxel, Taxol, Carboplatin, Paraplatin, Placebo | CanariaBio Inc., Gynecologic Oncology Group, Iqvia Pty Ltd | Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms | 09/25 | 08/27 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel | Seagen Inc. | Carcinoma, Non-Small-Cell Lung | 07/26 | 07/28 | | |
NCT06095583: Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) |
|
|
| Recruiting | 3 | 756 | Europe, US, RoW | Tifcemalimab injection, toripalimab injection, Placebo for Tifcemalimab, Placebo for toripalimab | Shanghai Junshi Bioscience Co., Ltd. | Limited-stage Small Cell Lung Cancer (LS-SCLC) | 07/27 | 07/29 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Recruiting | 2/3 | 268 | Europe, Canada, US, RoW | Navtemadlin, KRT-232, Navtemadlin Placebo | Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation | Endometrial Cancer | 08/25 | 07/27 | | |
ELCIN, NCT05596409: ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study |
|
|
| Recruiting | 2 | 60 | Europe, US, RoW | Elacestrant | Stemline Therapeutics, Inc. | Metastatic Breast Cancer | 02/25 | 08/25 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
NCT06062420: A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 |
|
|
| Recruiting | 2 | 360 | Europe, Canada, Japan, US, RoW | Dostarlimab, Belrestotug, Nelistotug, GSK4381562 | GlaxoSmithKline, iTeos Therapeutics | Neoplasms, Head and Neck | 05/27 | 05/27 | | |
PALBO, NCT05135104: Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period |
|
|
| Recruiting | N/A | 650 | Europe | Palbociclib, Ibrance | Asociatia Oncohelp - Centrul de Oncologie Oncohelp, MDX Research | Metastatic Breast Cancer | 03/24 | 05/24 | | |
| Robak, Tadeusz |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
| Recruiting | 3 | 357 | Europe, Japan, US, RoW | Belantamab mafodotin, Pomalidomide, Dexamethasone, Bortezomib | GlaxoSmithKline | Multiple Myeloma | 01/24 | 05/29 | | |
|
|
|
|
|
|
|
|
|
|
|
BRUIN-MCL-321, NCT04662255: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) |
|
|
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) |
|
|
| Recruiting | 3 | 600 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/26 | 01/27 | | |
| Caspi, Oren |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight and Obesity | 02/29 | 02/29 | | |
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial |
|
|
| Completed | 3 | 731 | US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF) | 07/24 | 07/24 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 11/25 | 01/26 | | |
DETECT-HF, NCT06378632: AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM |
|
|
| Recruiting | N/A | 500 | US, RoW | Hearo App | Cordio Medical | Heart Failure | 07/24 | 12/24 | | |
| Vertes, Andras |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES) |
|
|
| Recruiting | 3 | 10000 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Overweight and Obesity | 02/29 | 02/29 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events |
|
|
| Completed | 2 | 233 | Europe, Japan, US, RoW | LY3473329, Placebo | Eli Lilly and Company | Lipoprotein Disorder | 03/24 | 03/24 | | |
NCT05514548: Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease |
|
|
| Completed | 2 | 265 | Europe, Canada, US, RoW | INV-202, None applicable, Placebo | Inversago Pharma Inc., Worldwide Clinical Trials | Diabetic Kidney Disease | 08/24 | 09/24 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 11/25 | 01/26 | | |
| Ayers, Sarah |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 07/25 | | |
NOSTRA, NCT04118192: -Feasibility Study: A Study Looking at Ultrasound Guided Biopsies for Breast Cancer |
|
|
| Active, not recruiting | N/A | 72 | Europe | Tumour bed core biopsy | University of Birmingham, Roche Pharma AG, Cancer Research UK | Breast Cancer | 12/25 | 12/25 | | |
| Ulanska, Malgorzata |
| Active, not recruiting | 3 | 368 | Europe, US, RoW | Abemaciclib, Fulvestrant, Placebo | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasm, Neoplasm Metastasis | 02/24 | 02/26 | | |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 07/25 | | |
GALAXIES Lung-301, NCT06472076: A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, Japan, RoW | Dostarlimab, Belrestotug, Pembrolizumab, Placebo | GlaxoSmithKline, iTeos Therapeutics | Lung Cancer, Non-Small Cell | 09/28 | 09/29 | | |
| Recruiting | 2 | 182 | Europe, RoW | 6-Thio-2'-Deoxyguanosine, 6-thio-dG, THIO, Cemiplimab, LIBTAYO® | Maia Biotechnology | Carcinoma, Non-Small-Cell Lung | 06/24 | 12/24 | | |
|
| Active, not recruiting | 1/2 | 49 | Europe, Japan, US, RoW | TAK-981, Pembrolizumab | Takeda, Takeda Development Center Americas, Inc. | Advanced or Metastatic Solid Tumors | 11/25 | 11/25 | | |
| Sadeh, Ben |
SUMMIT, NCT04847557: A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The Trial |
|
|
| Completed | 3 | 731 | US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF) | 07/24 | 07/24 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 11/25 | 01/26 | | |
| Piotrowski, Grzegorz |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
NCT05652322: Prolonged Intravenous Therapy Versus Early Initiation of an Oral Loop Diuretic in Decompensated Heart Failure |
|
|
| Recruiting | 2/3 | 200 | Europe | Furosemide Pill 150% equivalent iv dose, Furosemide Pill 200% equivalent iv dose, Furosemide Injection | Jan Kochanowski University | Heart Failure | 12/23 | 03/24 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 11/25 | 01/26 | | |
| Moravsky, Gil |
NCT05180240: Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis |
|
|
| Recruiting | 2 | 100 | Europe, Canada, US, RoW | CardiolRx, Cannabidiol | Cardiol Therapeutics Inc. | Acute Myocarditis | 11/24 | 12/24 | | |
NCT05592275: A Study of LY3540378 in Participants With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF) |
|
|
| Recruiting | 2 | 456 | Europe, Canada, Japan, US, RoW | LY3540378, Placebo | Eli Lilly and Company | Heart Failure, Heart Failure With Preserved Ejection Fraction | 11/25 | 01/26 | | |
NCT03720535: COMMUNITY STUDY- A Study to Collect Information Related to the Cordio System |
|
|
| Recruiting | N/A | 150 | RoW | Cordio Medical | Cordio Medical | Heart Failure | 02/22 | 02/22 | | |
NCT03438799: COMMUNITY STUDY- A Study to Collect Information for the Cordio System |
|
|
| Recruiting | N/A | 500 | RoW | Cordio System | Cordio Medical | Heart Failure | 04/22 | 04/22 | | |
| Smolewski, Piotr |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 3 | 350 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
| Recruiting | N/A | 70 | Europe | No Intervention | Takeda | Hodgkin Lymphoma | 06/26 | 06/26 | | |
| Gafton, Bogdan |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 12/24 | 07/25 | | |
